Cyclacel Pharmaceuticals, Inc. (CYCC)
After hours:
| Previous close | 2.0500 |
| Open | 2.1200 |
| Bid | 1.9700 x 100 |
| Ask | 2.0800 x 100 |
| Day's range | 1.9300 - 2.1200 |
| 52-week range | 1.3000 - 13.2000 |
| Volume | |
| Avg. volume | 830,885 |
| Market cap | 2.941M |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -21.5900 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.00 |
- GuruFocus.com
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Insights into CYCC's financial health and strategic advancements in oncology research during the first quarter of 2024.
GlobeNewswireCyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib -- First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of Concept Study -- Balance Sheet Bolstered with $8.0 million Private Placement Priced At-The-Market Under Nasdaq Rules -- Management to Host Conference Call at 4:30 pm EDT Today - BERKELEY HEIGHTS, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclace
- GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (888) 632-3384 / international call: (785
